M. Powers

发表

HSP90 Inhibition as an Anticancer Strategy: Novel Approaches and Future Directions

P. Workman, M. Powers, 2009 .

Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

Paul Workman, Rainer Cramer, Marketa Zvelebil, 2007, Cancer research.

Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX

P. Workman, P. Clarke, M. Valenti, 2013, Oncotarget.

Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.

P. Workman, P. Clarke, M. Powers, 2008, Cancer cell.

Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins

L. Pearl, P. Workman, P. Clarke, 2013, Oncogene.

Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen

R. V. van Montfort, P. Workman, R. T. te Poele, 2016, Journal of medicinal chemistry.

Inhibitors of the heat shock response: Biology and pharmacology

Paul Workman, P. Workman, M. Powers, 2007, FEBS letters.

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.

S. Plymate, P. Workman, J. Lyons, 2016, Cancer research.

Death by chaperone: HSP90, HSP70 or both?

P. Workman, P. Clarke, M. Powers, 2009, Cell cycle.

Targeting of multiple signalling pathways 90 molecular chaperone inhibitors

P. Workman, M. Powers, 2007 .

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

P. Workman, M. Powers, 2006, Endocrine-related cancer.

In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.

L. Pearl, P. Workman, R. Marais, 2007, Cancer research.

Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma

G. Morgan, P. Workman, D. Gonzalez, 2010, Leukemia.

Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone?

Caterina Barillari, Keith Jones, Paul Workman, 2010, Cell cycle.

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

L. Pearl, X. Barril, M. Drysdale, 2007, Molecular Cancer Therapeutics.

Discovery and validation of biomarkers to support clinical development of NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor

P. Workman, P. Clarke, M. Valenti, 2022, European Journal of Cancer.

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies

P. Workman, P. Clarke, Alan T. Henley, 2023, Journal of medicinal chemistry.

Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer.

P. Workman, M. Powers, 2007, Nature chemical biology.

Drugging the heat shock factor 1 pathway: Exploitation of the critical cancer cell dependence on the guardian of the proteome

P. Workman, Jennifer R. Smith, E. de Billy, 2009, Cell cycle.